PRIMARY OBJECTIVES:~Information about:~General and vulvar-cancer-specific quality of life before and after any treatment for newly diagnosed vulvar cancer~Treatment-related morbidity after any treatment for newly diagnosed vulvar cancer~Unmet needs of patients with newly diagnosed vulvar cancer~Satisfaction with care after any treatment for newly diagnosed vulvar cancer in Sweden.~OUTLINE:~The study is planned as a prospective, longitudinal multi-centre study in Sweden. Since 2017, the treatment of vulvar cancer patients has been accredited to four tertiary referral university hospitals in Sweden; the Sahlgrenska University hospital in Gothenburg, the Linköping University hospital, the Skåne University hospital in Lund and the Karolinska University hospital in Stockholm.~150 patients are estimated for inclusion during a time frame of about 18 months.~Eligible patients will be asked to complete a validated questionnaire at different points of time (before and after treatment). Calculating a response rate of about 50% - 60%, this will result in at least 80 completed questionnaires.~The questionnaires consist of the following parts:~European Organisation for Research and Treatment of Cancer (EORTC)-QLQ-C30~European Organisation for Research and Treatment of Cancer (EORTC)-QLQ-VU-34 (Vulva-specific module)~Hospital Depression and Anxiety Scale (HADS)~Supportive Care Needs Survey Short Form, excerpt (SCNS-SF34)~European Organisation for Research and Treatment of Cancer (EORTC)-PATSAT (Patient Satisfaction), excerpt~Demographic data~25 self-constructed (and validated) questions~RESULTS:~Results are expected to be available in 2021.
The aim of this prospective, longitudinal Swedish multi-center study is to assess the quality of life, treatment-related morbidity, unmet needs and satisfaction with care after treatment for vulvar cancer, evaluated by a validated questionnaire.